75A50325F80014↗
Exelan Pharmaceuticals Inc received this contract from Aspr/Orm-Sns, Office of Assistant Secretary for Preparedness and Response: $74.06M obligated so far for drugs and biologicals. It runs to 2027-06-29.
Key facts · data as of Oct 25, 2026
- Recipient
- Exelan Pharmaceuticals Inc
- Awarding agency
- Office of Assistant Secretary for Preparedness and Response (Department of Health and Human Services)
- Contracting office
- Aspr/Orm-Sns (75A503)
- Obligated to date
- $74.06M
- Potential value
- $74.06M
- Ends
- 2027-06-29
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 25, 2026.
Cite this page: SpendQuery, Award 75A50325F80014, data as of Oct 25, 2026, https://spendquery.com/award?id=CONT_AWD_75A50325F80014_7505_36F79720D0227_3600
Exelan Pharmaceuticals Inc: all federal awards · Department of Health and Human Services: spending · Aspr/Orm-Sns: what it buys · The follow-on: recompete brief
OSELTAMIVIR PHOSPHATE 75MG CAPSULES (NDC: 76282-0704-45); 10 CT. BLISTERS PACKS AND OSELTAMIVIR PHOSPHATE 30MG CAPSULES (NDC: 76282-0702-45); 10 CT. BLISTERS PACKS.
Up for re-bid: ends 2027-06-29. Recompete brief →
What it is
- Product or service
- Drugs and Biologicals (PSC 6505)
- Industry
- Pharmaceutical Preparation Manufacturing (NAICS 325412)
- Contracting office
- Aspr/Orm-Sns (75A503)
- Competition
- Full and open competition · 3 offers received
- Pricing
- Firm fixed price
- How it was bought
- GSA Schedule · under 36F79720D0227
- Solicitation
- 75A50325Q00001
- Where the work is
- Palm Beach, FL · district FL-23
- Funding law
- COVID-19 laws
Obligations by fiscal year
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
Subcontractors: where the money went next
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
Every action
3 actions since 2025-06-29. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2025-07-18 | P00002 | Administrative change | $0 | OSELTAMIVIR PHOSPHATE 30MG CAPSULES CHANGE NDC FROM NDC 47781-468-13 TO NDC: 76282-0702-45); 10 CT. CAPSULES PACKS. |
| 2025-06-30 | P00001 | Administrative change | $0 | OSELTAMIVIR PHOSPHATE 75MG CAPSULES (NDC: 76282-0704-45); 10 CT. BLISTERS PACKS AND OSELTAMIVIR PHOSPHATE 30MG CAPSULES (NDC: 76282-0702-45); 10 CT. BLISTERS PACKS. |
| 2025-06-29 | 0 | $74.06M | OSELTAMIVIR PHOSPHATE 75MG CAPSULES (NDC: 76282-0704-45); 10 CT. BLISTERS PACKS AND OSELTAMIVIR PHOSPHATE 30MG CAPSULES (NDC: 76282-0702-45); 10 CT. BLISTERS PACKS. |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-25). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗